Claude has discovered a previously unknown enzyme system hidden in the DNA of bacteriophages. Beside the enzyme’s gene sits a long array of repeating DNA—a structure that looks somewhat similar to CRISPR. We don’t yet understand what this system does, but only a handful of known systems share its features, and all of them are able to cut, copy, and paste DNA. Historically, the discovery of such programmable systems has helped revolutionize medicine. CRISPR, for instance, is now the foundation of genetic medicines. But it will take much more work to learn what this system does, and whether it can be put to similar use. Read more: anthropic.com/news/claude-di…

New on the Science Blog: Yes, Claude can do Nine Loops. Theoretical physicists predict how particles behave using formulas called scattering amplitudes. These are notoriously hard to compute, so researchers work with layers of increasingly fine corrections called “loops”—each added loop makes the answer more precise but takes exponentially more computation. Most calculations stop at two or three loops. Eight loops was the previous record in a simplified model physicists use as a testing ground (planar N=4 super-Yang-Mills), set by SLAC's Lance Dixon and collaborators. Last month, physicist and science writer @4gravitons issued a challenge: could an AI push past eight loops in this model, using only the compute budget an academic could reasonably access? Given a single prompt describing the nine-loop problem, Claude ran largely unsupervised for days in Claude Science and solved it using methods developed by Dixon and his colleagues, at a total cost of a few thousand dollars. Dixon independently verified the result, and von Hippel wrote about the experience for our blog. Read more: anthropic.com/research/yes-c…

With @GoogleDeepMind, @emblebi, and research partners, we’re making AI-predicted protein complex structures for 2,800+ viruses openly available. This gives scientists a head start in preparing for potential outbreaks.

Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student. The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out. It’s easy to dismiss this as a one-off or curiosity, but we’ve repeatedly seen a pattern where AI performance in new intellectual domains goes from weak to superhuman in a matter of a few years. In 2023 models struggled to do math at the level of an average high-school student. In 2024 they started to do well on math competitions for the best high-schoolers in the country, in 2025 they started to solve minor open problems, in early 2026 more significant open problems, and in late 2026 they are beginning to solve the top few open problems in all of mathematics. We believe AI for biology is on a similar exponential trend. The main difference between biology and mathematics, of course, is that math can be done purely theoretically, while biology requires experimentation. Some have used this to draw the conclusion that AI’s utility in biology will be limited. We think this is wrong. As we’ve demonstrated today, humans can collaborate with AI to perform the experiments, validate key results in a few weeks and, if necessary, work with the AI to iterate on what they find. Eventually it may even be possible for Claude itself to safely perform the experiments by autonomously controlling lab equipment, with appropriate safeguards in place, but we aren’t doing that today (our lab is also a BSL1/BSL2 facility that doesn't handle materials dangerous to humans). More broadly, biomedical advancement has many stages — from fundamental biology discoveries, to translational research, to drug discovery, clinical trials, and finally the actual delivery of medicines and health care to patients. We are also interested in these later stages, but even simply accelerating the first stage of fundamental biological discoveries has the potential to speed up and broaden the entire pipeline. Improving our understanding of biology and sharpening biologists’ tools can drive forward all of the later stages, for example by identifying new drug targets, finding new therapeutic modalities, allowing for more precise measurement, and speeding up the experimental loop which itself further accelerates our understanding of biology. This will not in itself speed up clinical trial times, but if it succeeds it could greatly increase the number of promising candidates that go into the pipeline — an increase in throughput even though latency remains. In Machines of Loving Grace, I wrote about AI’s potential to “cure most diseases in 5-10 years” — a goal that sounds impossible, but one I believe is just barely possible if AI is applied to every stage of the pipeline. The first step is showing that AI can first help with, and then drive, biological discoveries. Claude’s discovery is the latest in a line of related prior work that goes back decades, beginning with systems like CRISPR, and continuing with discoveries like the bridge recombinase and VIPR in the past few years. Recently, there has been heightened interest in systems based on reverse transcriptase (RT) enzymes, the enzyme underlying the system Claude identified. And most recently, a Stanford team working independently described a novel RT system with an associated non-coding array that is in some ways similar to the one Claude found, though they are distinct systems that evolved independently from each other. I believe that we’re at the very beginning of finding such systems and developing them into powerful tools for biotechnology. I’m proud of the resources Anthropic has invested in accelerating the public benefits of AI through the life sciences, and we’re aiming both to grow our life sciences team and to work with other scientists to extend this approach to a broad range of problems. If you have a proposal for a research collaboration or are interested in joining our life sciences team, please reach out.

Please welcome GPT-6 Sol and GPT-6 Luna to the GPT-6 universe. GPT-6 Sol and Luna build on the advances behind GPT-6 Astra, bringing much of its strengths into faster and more affordable models to support work at scale. We’ve also made caching and inference more efficient, and we’re passing the savings directly to you: 50% lower API prices for Sol and Luna compared with GPT‑5.6 promotional pricing.

Introducing Claude Opus 5.5, the first model in our new Claude 5.5 family. It performs at the level of Claude Fable 5.1 for most tasks, and costs 40% less to run than Opus 5.

We’re working with an independent advisory group of mathematicians to help OpenAI responsibly share advances in AI and mathematics. The group will advise on how we assess and communicate new mathematical results, uphold academic and professional standards, and build tools that support mathematical research and learning. Through this work, we want mathematicians to be at the center of shaping how AI supports mathematical understanding and how its benefits reach the wider community. openai.com/index/advisory-gr…

OpenAI o1 is now out of preview in ChatGPT. What’s changed since the preview? A faster, more powerful reasoning model that’s better at coding, math & writing. o1 now also supports image uploads, allowing it to apply reasoning to visuals for more detailed & useful responses.

Grok 4.7 is here. It's a notable improvement over Grok 4.6 at the same price and speed.

After co-inventing ChatGPT, I kept asking myself: why have superhuman chat models not led to AGI? I’ve spent the last 2 years in stealth building a new way to train models (RLCD), and a new type of frontier AI model that we are releasing today: Jev • 20-200x faster • 40-400x cheaper (w/ output tokens free) • Frontier composable intelligence optimized for decisions AFAICT the shortest path to AI-based economic revolution

The world deserves confidence that American companies developing increasingly capable AI will act responsibly, especially as the trajectory of progress has steepened. Every frontier lab must deliver on this, and there is no reason any of us should come to work if we cannot. We welcome a federal framework that sets consistent safety requirements for frontier AI. But we do not believe we need to wait for an anti-trust exemption or legislation to begin the work of providing this confidence. Consistent rules to manage frontier risk so that we can maximize the benefits are a good idea (and we are excited by ideas like independent auditors). Years ago, companies like ours developed things like Responsible Scaling Policies and Preparedness Frameworks. Those were good for that moment, and focused primarily on the deployment of completed models, not what happens during their development process. Today's shift to focusing on safe development and evaluation will need new tools. For example, at OpenAI we now formulate explicit safety cases in advance of frontier reinforcement learning runs we expect to significantly increase capability, in addition to the safety work we have long done in advance of model releases. We hope that other companies will learn from our approaches and propose their own; we think shared standards for misalignment, monitoring, and safety will lead to better outcomes. We look forward to collaborating with our colleagues across the industry to formulate the best version of these. When we talk about “pacing”, we do not mean “stopping”. Progress has been rapid and will continue to be. But it should be slower than it otherwise could be; interventions like safety cases and monitoring have significant costs. Pacing will be well worth this cost; no amount of American competitive pressure should justify recklessness, or let capabilities get ahead of alignment and monitoring. Where we will need the help of our government is for international coordination. But first we should do what we can ourselves.

Excited to share our fully integrated documentation experience for humans and agents, right in @GoogleAIStudio!! I have wanted this for 2.5 years, sorry it took so long, but the first step towards an ever further reimagined experience. Great work by @timeyoutakeit & team

🚀 Introducing DeepSeek-V4.1-Flash: smarter, faster, more efficient. 🔹 Introducing the smallest model in our new architecture family, with native visual understanding. 🔹 Designed for greater capability, faster inference, higher throughput, and scaling to larger models. 1/6

Anthropic’s Economics team is sharing a new model of how AI might affect economic growth, jobs, wages, and more by 2030. Explore the scenarios, tell us what you think will happen, and see how your answers compare to more than 10,000 Americans. anthropic.com/institute/econ…

We’re sharing a solution to the Navier-Stokes Millennium Prize Problem, one of the deepest problems at the frontier of mathematics. The proof was produced by a group of agents, using an OpenAI next-generation model significantly more capable than GPT-6 Astra. The problem concerns whether the description of smooth three-dimensional fluid motion modeled by the Navier-Stokes equations can break down. It has remained unresolved for roughly 90 years.

This model represents a step-function improvement on many benchmarks, and its training is ongoing. Our internal model group arrived at the Navier–Stokes solution in 88 hours, using around 10,000 coordinating AI agents. Throughout the effort, we maintained the strict safeguards—including monitoring and isolation—that we apply to all our frontier evaluations.